Leticia Berenguer-Ruiz1, Juana Gimenez-Martinez2, Antonio Palazón-Bru3, Angel Perez Sempere4,5. 1. Neurology Service, Hospital Marina Baixa, Alicante, Spain. 2. Neurology Service, Hospital General Universitario de Alicante, 03010, Alicante, Spain. 3. Department of Clinical Medicine, Miguel Hernández University, Sant Joan d'Alacant, Spain. 4. Neurology Service, Hospital General Universitario de Alicante, 03010, Alicante, Spain. angel.perezs@umh.es. 5. Department of Clinical Medicine, Miguel Hernández University, Sant Joan d'Alacant, Spain. angel.perezs@umh.es.
Abstract
OBJECTIVE: To evaluate the effect of discontinuation of different disease-modifying therapies (DMTs) before pregnancy with respect to the occurrence of relapses and pregnancy outcomes. METHODS: Women with multiple sclerosis who desire to bear children were followed prospectively. Demographic data, clinical characteristics, and the information on the use of DMTs were collected. A multivariate analysis was used to assess the relationship between relapses and the prior use of different DMTs. RESULTS: The present study assessed 75 consecutive pregnancy plans (66 women), 65 of which resulted in pregnancy. The mean age of the participants was 32.1 ± 4.2 years, and the mean disease duration was 6.1 ± 4.2 years. No relapses before pregnancy were reported in the group of women who maintained their DMT until pregnancy confirmation, while 14 relapses were reported in 12/42 women (29%) who discontinued DMT before pregnancy. During pregnancy, patients on natalizumab or fingolimod before pregnancy had a higher rate of relapses. Most women restarted their previous DMT after delivery within the first trimester. The relapse rate in postpartum was 0.07. CONCLUSIONS: Disease-modifying therapies received influences the risk of relapse and disease progression from women who are planning pregnancy. The risk of relapse during pregnancy was significantly higher in the group of women treated with natalizumab or fingolimod compared to the group of women treated with interferon beta or glatiramer acetate. The postpartum risk of relapses was lower than that found in previous reports.
OBJECTIVE: To evaluate the effect of discontinuation of different disease-modifying therapies (DMTs) before pregnancy with respect to the occurrence of relapses and pregnancy outcomes. METHODS:Women with multiple sclerosis who desire to bear children were followed prospectively. Demographic data, clinical characteristics, and the information on the use of DMTs were collected. A multivariate analysis was used to assess the relationship between relapses and the prior use of different DMTs. RESULTS: The present study assessed 75 consecutive pregnancy plans (66 women), 65 of which resulted in pregnancy. The mean age of the participants was 32.1 ± 4.2 years, and the mean disease duration was 6.1 ± 4.2 years. No relapses before pregnancy were reported in the group of women who maintained their DMT until pregnancy confirmation, while 14 relapses were reported in 12/42 women (29%) who discontinued DMT before pregnancy. During pregnancy, patients on natalizumab or fingolimod before pregnancy had a higher rate of relapses. Most women restarted their previous DMT after delivery within the first trimester. The relapse rate in postpartum was 0.07. CONCLUSIONS: Disease-modifying therapies received influences the risk of relapse and disease progression from women who are planning pregnancy. The risk of relapse during pregnancy was significantly higher in the group of women treated with natalizumab or fingolimod compared to the group of women treated with interferon beta or glatiramer acetate. The postpartum risk of relapses was lower than that found in previous reports.
Authors: Emilio Portaccio; Angelo Ghezzi; Bahia Hakiki; Andrea Sturchio; Vittorio Martinelli; Lucia Moiola; Francesco Patti; Gian Luigi Mancardi; Claudio Solaro; Maria Rosaria Tola; Carlo Pozzilli; Laura De Giglio; Rocco Totaro; Alessandra Lugaresi; Giovanna De Luca; Damiano Paolicelli; Maria Giovanna Marrosu; Giancarlo Comi; Maria Trojano; Maria Pia Amato Journal: J Neurol Neurosurg Psychiatry Date: 2014-01-08 Impact factor: 10.154
Authors: Yara Dadalti Fragoso; Mike Boggild; Miguel Angel Macias-Islas; Adriana Carra; Kirsty Deborah Schaerer; Adriana Aguayo; Sandra Maria Garcia de Almeida; Marcos Papais Alvarenga; Regina Maria Papais Alvarenga; Soniza Vieira Alves-Leon; Walter Oleschko Arruda; Joseph Bruno Bidin Brooks; Elizabeth Regina Comini-Frota; Maria Lucia Brito Ferreira; Alessandro Finkelsztejn; Juliana Marcon Szymanski Finkelsztejn; Lucas Dias de Freitas; Andre Serafin Gallina; Paulo Diniz da Gama; Sergio Georgetto; Maria Cristina B Giacomo; Sidney Gomes; Marcus Vinicius Magno Gonçalves; Anderson Kuntz Grzesiuk; Damacio Ramon Kaimen-Maciel; Josiane Lopes; Giselle A Lourenco; Fabiola Rachid Malfetano; Nivea Macedo Oliveira Morales; Rogerio de Rizo Morales; Celso Luis Silva Oliveira; Patricia Onaha; Cristiane Patroclo; Sonia Beatriz Felix Ribeiro; Taysa Alexandrino Gonsalves Jube Ribeiro; Heidi Johanna Salminen; Patricia Santoro; Marcos Seefeld; Paula Vallegas Soares; Adriana Tarulla; Claudia Cristina Ferreira Vasconcelos Journal: Clin Neurol Neurosurg Date: 2012-05-26 Impact factor: 1.876
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Iris Kleerekooper; Zoé L E van Kempen; Cyra E Leurs; Iris Dekker; Theo Rispens; Birgit I Lissenberg-Witte; Caspar E P van Munster; Brigit A de Jong; Bob W van Oosten; Bernard M J Uitdehaag; Mike P Wattjes; Joep Killestein Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-12-05
Authors: Wei Zhen Yeh; Putu Ayu Widyastuti; Anneke Van der Walt; Jim Stankovich; Eva Havrdova; Dana Horakova; Karolina Vodehnalova; Serkan Ozakbas; Sara Eichau; Pierre Duquette; Tomas Kalincik; Francesco Patti; Cavit Boz; Murat Terzi; Bassem I Yamout; Jeannette Lechner-Scott; Patrizia Sola; Olga G Skibina; Michael Barnett; Marco Onofrj; Maria José Sá; Pamela Ann McCombe; Pierre Grammond; Radek Ampapa; Francois Grand'Maison; Roberto Bergamaschi; Daniele L A Spitaleri; Vincent Van Pesch; Elisabetta Cartechini; Suzanne Hodgkinson; Aysun Soysal; Albert Saiz; Melissa Gresle; Tomas Uher; Davide Maimone; Recai Turkoglu; Raymond Mm Hupperts; Maria Pia Amato; Franco Granella; Celia Oreja-Guevara; Ayse Altintas; Richard A Macdonell; Tamara Castillo-Trivino; Helmut Butzkueven; Raed Alroughani; Vilija G Jokubaitis Journal: Neurology Date: 2021-04-20 Impact factor: 9.910